To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with JavaScript enabled.
This website is not optimized for your browser, as configured.
Participation

Driving Progress Against Childhood Cancer

Boys wearing soccer jerseys running

Childhood cancer is rare, yet about 11,050 children in the United States under the age of 15 will be diagnosed with cancer in 2020. While many types of cancers can appear in people of all ages, we know that kids are not just little adults and treatment often needs to be different. Pediatric clinical trials allow for the development of medicines with the unique needs of children in mind and have helped drive great strides against childhood cancer (1). Yet, there is still much more to learn and new advancements to be made.

Currently Lilly is working on an innovative approach to support advancing pediatric research by using master protocols to study new treatments for cancer patients. Master protocols are a novel way to study multiple research questions about several different drugs, diseases or conditions all in one clinical trial (instead of having to have multiple clinical trials) (2). Some of the potential benefits of this approach are to help to quickly test and answer scientific questions, compare different treatment options, reduce the cost of the study, reduce the time to set up new studies or enroll patients to aid in our ability to create medicines for our pediatric cancer patient population faster than we normally would under a non-master protocol clinical trial. 

An example of some of our master protocol clinical trials in pediatrics can be found at LillyTrialGuide.com with the heading in the title of the study "CAMPFIRE." CAMPFIRE stands for "Children’s and Young Adult Master Protocol for Innovative Pediatric Research." CAMPFIRE is a platform to accelerate the development of novel treatments for pediatric and young adult patients with cancer. This platform uses innovative designs and an overarching infrastructure to harness the benefits of shared data and operational efficiencies. The investigational agents on the trial will change over time based on the criteria established in the sub-protocols.

Explore the infographic below to learn more about the landscape of childhood cancer and the role of pediatric research in powering progress.

DrivingProgressAgainstChildhoodCancer Infographic 2Mar2020-01

Citations:

  1. https://www.cancer.gov/types/childhood-cancers
  2. J. Woodcock, L.M. LaVange. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med., 377 (2017), pp. 62-70

Blog post originally appeared on LillyPad.

Tags: Cancer, Infographic, Pediatric Research,

Recent Articles

COVID-19TrialsUnderway FeatureImage 22June2020

Lilly’s COVID-19 Clinical Trials are Underway

LTGBlogAuthors LillyGuestAuthorIcon 20July2018
Lilly Guest Author
June 22nd, 20206 minute read

Lilly has worked quickly to launch studies of potential COVID-19 antibody treatments. Find out what makes antibodies an intriguing scientific and medical option.

COVID-19ResearchTypes FeatureImage1 19May2020

Types of Clinical Research for COVID-19

Leigh Anne Naas Headshot
Leigh Anne Naas
June 3rd, 20206 minute read

As the world works to quickly learn about COVID-19, a mix of research studies is underway. This guide explains the different types of COVID-19 studies and what researchers hope to learn from them.

AStoryofResearchVolunteers FeatureImage 6May2020-01

Meet Four Research Volunteers

Leigh Anne Naas Headshot
Leigh Anne Naas
May 13th, 20201 minute read

Over 2 million brave people take part in clinical trials every year, testing new treatments that may make life better. Meet four of those people.

InnovationInClinicalTrials TweetChatBlog 14May2020-01

Tweet Chat: Uncovering Innovation in Clinical Trials

Leigh Anne Naas Headshot
Leigh Anne Naas
May 27th, 20203 minute read

On International Clinical Trials Day, we hosted a tweet chat to generate conversation on #ClinicalTrialInnovation. If you didn’t have a chance to attend, we’ve broken down the key takeaways here.

A De-centralized Response Featured Image

Clinical Trials: A De-Centralized Response

BlogAuthor Don2 3Dec2019
Don Harder
May 4th, 20203 minute read

The quick adoption and scaling of decentralized trials will be one of the positive outcomes of having to look at the world of clinical trials in a different way. Learn more about the shift.